Christopher J. Tovey - Jul 5, 2022 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role: EVP, COO & Managing Director E
Signature: By: /s/Adam Guttmann, as attorney in fact For: Christopher J Tovey
Stock symbol: JAZZ
Transactions as of: Jul 5, 2022
Transactions value $: -$833,359
Form type: 4
Date filed: 7/7/2022, 05:17 PM
Previous filing: May 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JAZZ	Ordinary Shares	Options Exercise	$80.60	+4.03K	+25.45%	$0.02^*	19.9K	Jul 5, 2022	Direct
transaction	JAZZ	Ordinary Shares	Sale	-$645K	-4.03K	-20.29%	$160.00	15.8K	Jul 5, 2022	Direct
transaction	JAZZ	Ordinary Shares	Sale	-$188K	-1.18K	-7.43%	$160.00	14.7K	Jul 5, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAZZ	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-4.03K	-50.01%	$0.00	4.03K	Jul 5, 2022	Ordinary Shares	4.03K	$0.02	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger.

Content

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger.